+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Laboratory control of continuous intravenous heparin therapy with Howel time and activated partial thromboplastin time. A prospective, randomized and blind study



Laboratory control of continuous intravenous heparin therapy with Howel time and activated partial thromboplastin time. A prospective, randomized and blind study



Angiology 36(6): 363-369



Although heparin has been used extensively to treat Deep Venous Thrombosis (DVT) and arterial ischemia (AI), controversy still exists regarding optimal dosage and the need for monitoring. Different authors have employed various test with variable results. Others, however, persist in giving heparin without laboratory control. This study was made in order to compare, in a prospective, randomized and blind manner, two coagulation tests, namely: Howel Time (HT) and Activated Partial Thromboplastin Time (APTT), in controlling the dose of heparin given by continuous intravenous infusion in DVT and AI. Our results show no significant difference in complications and failures of the therapy with either test, although significantly higher doses of heparin were needed to maintain APTT within therapeutic range than those needed to keep HT within a similar range.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 005787583

Download citation: RISBibTeXText

PMID: 4025944

DOI: 10.1177/000331978503600605


Related references

In vitro comparison of the thrombin time and activated partial thromboplastin time in the laboratory control of heparin therapy. American Journal of Clinical Pathology 60(5): 648-650, 1973

Laboratory controls of heparin therapy with thrombin time, partial thromboplastin time and activated recalcification time. Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete 44(8): 235-240, 1989

Laboratory control of heparin therapy with the activated partial thromboplastin time test. Current Therapeutic Research Clinical and Experimental 11(6): 390-396, 1969

Evaluation of point-of-care activated partial thromboplastin time testing by comparison to laboratory-based assay for control of intravenous heparin. Angiology 60(3): 358-361, 2009

Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. Annals of PharmacoTherapy 45(7-8): 861-868, 2011

Laboratory monitoring of heparin therapy--the effect of different salts of heparin on the activated partial thromboplastin time. American Journal of Clinical Pathology 74(4 Suppl): 569-574, 1980

The relationship between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. Jgim 10(4 Suppl ): 38, 1995

The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. Archives of Internal Medicine 156(15): 1677-1681, 1996

Comparative analysis of the activated clotting time heparin concentration and activated partial thromboplastin time in monitoring heparin therapy. American Journal of Clinical Pathology 89(3): 429, 1988

Graphic analysis of activated partial thromboplastin time in inpatients receiving intravenous heparin therapy. American Journal of Clinical Pathology 100(3): 340, 1993

The activated partial thromboplastin time as a control in heparin therapy. Southern Medical Journal 60(6): 594-598, 1967

Control of heparin therapy with an activated partial thromboplastin time. Netherlands Journal of Medicine 16(3): 129-135, 1973

Control of heparin therapy. Sensitivity of the activated partial thromboplastin time for monitoring the antithrombotic effects of heparin. Journal of Laboratory and Clinical Medicine 73(2): 320-326, 1969

The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb. Journal of Thrombosis and Thrombolysis 14(2): 91, 2002

A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. New England Journal of Medicine 287(7): 324-327, 1972